From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53]. Here, GCG is linked to diabetes mellitus.